Evidence map›Paper›PMID 39514585›Full record

ArticlePLoS pathogens2024

Structural basis for human DPP4 receptor recognition by a pangolin MERS-like coronavirus.

Mo Yang, Zehou Li, Jing Chen, Yang Li, Ran Xu, Meihua Wang, Ying Xu, Rong Chen, Weiwei Ji, Xiaoxia Li and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Mo YangCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.
Zehou LiCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.
Jing ChenKey Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Yang LiKey Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Ran XuCentre in Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao, China.
Meihua WangKey Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Ying XuCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.
Rong ChenInstitute of Veterinary Medicine, Jiangsu Academy of Agricultural Sciences, Key Laboratory of Veterinary Biological Engineering and Technology, Ministry of Agriculture, Nanjing, China.
Weiwei JiCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.
Xiaoxia LiCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.
Jiayu WeiCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.
Zhengrong ZhouCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.
Minjie RenCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.
Ke MaCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.
Jiayu GuanCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.
Guoxiang MoCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.
Peng ZhouGuangzhou Laboratory, Guangzhou International Bio Island, Guangzhou, Guangdong, China.
Bo ShuKey Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Jingjing GuoCentre in Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao, China.
Yuan YuanSchool of Life Sciences, Anhui University, Hefei, Anhui, China.
Zheng-Li ShiKey Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
Shuijun ZhangCollege of Life Sciences, Nanjing Agricultural University, Nanjing, China.ORCID 0000-0002-9875-1501

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) and the pangolin MERS-like coronavirus MjHKU4r-CoV-1 employ dipeptidyl peptidase 4 (DPP4) as an entry receptor. MjHKU4r-CoV-1 could infect transgenic mice expressing human DPP4. To understand the mechanism of MjHKU4r-CoV-1 entry into cells, we determined the crystal structures of the receptor binding domain (RBD) of MjHKU4r-CoV-1 spike protein bound to human DPP4 (hDPP4) and Malayan pangolin DPP4 (MjDPP4), respectively. The overall hDPP4-binding mode of MjHKU4r-CoV-1 RBD is similar to that of MERS-CoV RBD. MjHKU4r-CoV-1 RBD shows higher binding affinity to hDPP4 compared to the bat MERS-like coronavirus Ty-BatCoV-HKU4. Via swapping residues between MjHKU4r-CoV-1 RBD and Ty-BatCoV-HKU4 RBD, we identified critical determinants on MjHKU4r-CoV-1 that are responsible for virus usage of hDPP4. Our study suggests that MjHKU4r-CoV-1 is more adapted to the human receptor compared to the bat HKU4 coronavirus and highlights the potential of virus emergence into the human population.

Indexed as

Dipeptidyl Peptidase 4Middle East Respiratory Syndrome CoronavirusPangolinsSpike Glycoprotein, CoronavirusAnimalsCoronavirus InfectionsHumansMiceProtein BindingReceptors, VirusVirus InternalizationDipeptidyl Peptidase 4DPP4 protein, humanReceptors, VirusSpike Glycoprotein, Coronavirus

Identifiers

PMID39514585
PMCPMC11578449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.